Kyung Nam Pharm, 190won rights offering to existing shareholders

Kyung Nam Pharm 21announced that it had decided to conduct a rights offering with a general offering of unsubscribed shares to raise won for working capital and other purposes. The company said it plans to use the proceeds to meet short-term funding needs. The decision was publicly announced in a company filing.190announced that it had decided to conduct a rights offering with a general offering of unsubscribed shares to raise won for working capital and other purposes. The company said it plans to use the proceeds to meet short-term funding needs. The decision was publicly announced in a company filing.

In a rights offering followed by a general offering of unsubscribed shares, new shares are first allocated to existing shareholders, and any remaining shares are offered to the general public. Existing shareholders receive priority in the allocation of new shares. If any shares go unsubscribed, they are offered through a general offering.

The company’s announcement stated that the funds raised would be used for working capital and other purposes. Working capital generally refers to the cash needed to run a business. The specific uses should be checked in the disclosure document.

This disclosure did not include detailed terms such as the specific offering price, the number of shares to be issued, or the subscription schedule for the rights offering. Investors and other interested parties can check the company’s disclosure documents for specific details. The company stated that it would provide related information in its disclosures.

Kyung Nam Pharm is a pharmaceutical company listed on KOSDAQ. The company announced this financing decision in a disclosure and plans to release details through a further disclosure. Shareholders and investors should make any necessary checks based on the disclosure.